In this study, we demonstrate that LAPTM4B is markedly upregulated in EGFR-mutant NSCLC, with further elevation observed in tumors from patients who have developed resistance to EGFR-TKI therapy. Here, LAPTM4B is linked to non-small cell lung carcinoma.